Last reviewed · How we verify

Gabapentin 400 mg

Mit Ghamr Oncology Center · FDA-approved active Small molecule Quality 5/100

Gabapentin 400 mg is a Small molecule drug developed by Mit Ghamr Oncology Center. It is currently FDA-approved.

At a glance

Generic nameGabapentin 400 mg
SponsorMit Ghamr Oncology Center
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Gabapentin 400 mg

What is Gabapentin 400 mg?

Gabapentin 400 mg is a Small molecule drug developed by Mit Ghamr Oncology Center.

Who makes Gabapentin 400 mg?

Gabapentin 400 mg is developed and marketed by Mit Ghamr Oncology Center (see full Mit Ghamr Oncology Center pipeline at /company/mit-ghamr-oncology-center).

What development phase is Gabapentin 400 mg in?

Gabapentin 400 mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing